HC Wainwright Issues Positive Forecast for SCTX Earnings

Scribe Therapeutics Inc. (NASDAQ:SCTX) – HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Scribe Therapeutics in a note issued to investors on Thursday, September 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.42) per share for the quarter, up from their prior forecast of ($1.02). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Scribe Therapeutics’ current full-year earnings is ($3.68) per share. HC Wainwright also issued estimates for Scribe Therapeutics’ Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($3.68) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($2.52) EPS.

SCTX has been the topic of a number of other research reports. Zacks Research raised shares of Scribe Therapeutics to a “hold” rating in a research note on Tuesday, September 1st. Wells Fargo & Company assumed coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 price target on the stock. Leerink Partners began coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price objective for the company. Wall Street Zen upgraded shares of Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. Finally, Guggenheim assumed coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $50.00 target price on the stock. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.75.

Scribe Therapeutics Price Performance

SCTX stock opened at $28.67 on Monday. Scribe Therapeutics has a 1 year low of $17.31 and a 1 year high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX) last posted its earnings results on Wednesday, September 2nd. The company reported ($3.84) EPS for the quarter, topping analysts’ consensus estimates of ($6.20) by $2.36. The company had revenue of $1.92 million during the quarter, compared to the consensus estimate of $3.10 million.

Insider Buying and Selling

In related news, Director Behzad Aghazadeh purchased 2,383,333 shares of Scribe Therapeutics stock in a transaction on Friday, July 24th. The shares were purchased at an average price of $15.15 per share, for a total transaction of $36,107,494.95. Following the transaction, the director owned 3,080,983 shares of the company’s stock, valued at approximately $46,676,892.45. This represents a 341.62% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Bio Fund Ii L.P. Ah purchased 333,333 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was bought at an average cost of $15.00 per share, with a total value of $4,999,995.00. Following the purchase, the insider owned 2,385,075 shares of the company’s stock, valued at approximately $35,776,125. This trade represents a 16.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 3,727,237 shares of company stock valued at $56,291,746 over the last 90 days.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.